Regeneron Pharmaceuticals Inc.’s coronavirus antibody cocktail – the experimental treatment that U.S. President Donald Trump received – significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate Covid-19.

The U.S. government will pay as much as $1.19 billion to Eli Lilly to secure nearly 1 million doses of the company’s experimental Covid-19 antibody treatment, a drug similar to a treatment that U.S. President Donald Trump received.

A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes a higher complication rate with Covid-19 versus the flu.

German biotech company Evotec said on Monday the company had received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody (mAbS) drugs for the prevention of severe Covid-19.

Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.

The U.S. government awarded $486 million to AstraZeneca Plc to develop and secure supplies of up to 100,000 doses of Covid-19 antibody treatment, a similar class of drug that was used in treating President Donald Trump.

Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.

President Donald Trump was treated with an experimental antibody cocktail for Covid-19 and moved to a military hospital as a precautionary measure, White House officials said.

Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).

A rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.